Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials

Martina Kovac, Himal Lal, Anthony L. Cunningham, Myron J. Levin, Robert W. Johnson, Laura Campora, Antonio Volpi, Thomas C. Heineman*, for the ZOE-50/70 Study Group

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

17 Citations (Scopus)
300 Downloads (Pure)

Abstract

Background: An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively). Methods: Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases. Results: In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported. Conclusions: HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).

Original languageEnglish
Pages (from-to)1537-1541
Number of pages5
JournalVaccine
Volume36
Issue number12
Early online date17 Feb 2018
DOIs
Publication statusPublished - 14 Mar 2018

Keywords

  • Complications
  • Herpes zoster
  • Hospitalisation
  • Postherpetic neuralgia
  • Vaccine efficacy
  • Varicella-zoster virus

Fingerprint Dive into the research topics of 'Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials'. Together they form a unique fingerprint.

Cite this